Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients.

Breast cancer research and treatment - 1 Jul 2024

Richman Juliet, Schuster Gene, Buus Richard, Lopez-Knowles Elena, Dowsett Mitch

Abstract excerpt

BACKGROUND: Risk of recurrence from primary ER+ breast cancer continues for at least 20 years. We aimed to identify clinical and molecular features associated with risk of recurrence after 10 years. METHODS: ER+ breast cancers from patients with and without recurrence were analysed with the BC360 NanoString Panel and an 87 gene targeted-exome panel. Frequency of clinical, pathologic and molecular characteristics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to GATA3 Transcription Factor

Share to Neoplasm Recurrence, Local

Share to Prognosis

Share to Receptors, Estrogen

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 38709373
DOI: 10.1007/s10549-024-07311-z
PMCID: PMC11182842

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients.PMID 38709373Read ↗

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.Semantic proximity Read ↗

Integrative analysis of pre-treatment RNA expression signatures and recurrent genomic alterations: Link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancerSemantic proximity Read ↗

Multi-state modeling associates proliferation genes with early estrogen receptor-positive breast cancer recurrence and survivalSemantic proximity Read ↗

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerSemantic proximity Read ↗

Multi-omic Profiling of Recurrence Risk Across Breast Cancer SubtypesSemantic proximity Read ↗

A microRNA Signature Associated with Early Recurrence in Breast CancerSemantic proximity Read ↗

Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohortSemantic proximity Read ↗

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrencesSemantic proximity Read ↗

Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence.Semantic proximity Read ↗

A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrencesSemantic proximity Read ↗

Gene Expression Profiles for Recurrence of Lymph Node-positive Primary Breast Cancer in Women Over 40 Years of AgeSemantic proximity Read ↗

Whole-exome sequencing of FFPE samples reveals mutations associated with Luminal A breast cancer recurrence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.